Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Biomedical research impacts all of us. I became curious about how drugs work after my mom was diagnosed with rheumatoid arthritis when I was a small boy. She received “gold shots” as treatment, which ...

Of the amount earned in 2024, $1.6 million came from Michael’s salary, which increased a little less than $200,000 compared with 2023 as part of his promotion, AbbVie said in its 2025 proxy ...

3. AbbVie Inc. (ABBV) AbbVie is a big cap pharmaceutical company which had one of the blockbuster drugs, Humira, over the last decade. But Humira recently went off patent. AbbVie has been trying ...

Effectiveness between the adalimumab biosimilars (Amjevita and Imraldi) and the original brand-name version (Humira) was comparable both in new users and for patients switching from the original ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its market share to biosimilar competitors. For six years straight, AbbVie’s Humira ...

Adalimumab (Humira; AbbVie) is one of the leading products in the biologics market, often used to treat immune and inflammatory conditions. Unlike other biosimilars, adalimumab biosimilars have unique ...

According to Chinese astrologer and divination Nan Yi, "Their lives will dramatically transform after 40." For some, this might take shape in their finances. For others, their relationships might ...

This old-school utility stock offers income investors the stability and track record many seek now and a solid 3.40% dividend. Consolidated Edison Inc. (NYSE: ED), through its subsidiaries ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit ...

AbbVie held onto almost all of the Humira market for more than a year after close copies of the drug were launched in early 2023. That changed when CVS Health removed Humira from its list of covered ...

AbbVie held onto almost all of the Humira market for more than a year after close copies of the drug were launched in early 2023. That changed when CVS Health (NYSE:CVS) removed Humira from its ...